ArticleFrontiers in immunology2026
Accelerated response and reduced chemotherapy with ruxolitinib-based regimen therapy in pediatric hemophagocytic lymphohistiocytosis: a retrospective comparison with HLH-94 regimen.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ruxolitinib combined with corticosteroids for the successful treatment of kawasaki disease-associated macrophage activation syndrome: a case report.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To compare the efficacy of a Ruxolitinib-based regimen versus the conventional HLH-94 protocol in children with newly diagnosed hemophagocytic lymphohistiocytosis (HLH). Methods: This single-center, retrospective historical control study enrolled 67 pediatric HLH patients who met the HLH-2004 diagnostic criteria. Patients treated with the HLH-94 regimen (dexamethasone plus etoposide) from 2022 to 2023 constituted the control group (Group C, n=40), while those treated with a response-guided, ruxolitinib-based regimen from 2024 comprised the treatment group (Group T, n=27). Primary endpoint was 12-month overall survival (OS). Secondary endpoints included early response, safety, and cumulative exposure to glucocorticoids and etoposide during the first 8 weeks of therapy. Results: Group T achieved a significantly higher complete response (CR) rate at week 2 compared to Group C (25.9% vs. 0%; P = 0.001). CR rates at weeks 4 and 8 were 55.5% vs. 35.0% (P = 0.096) and 78.0% vs. 70.0% (P = 0.481), respectively, with no significant difference in overall response rate. The 12-month OS (96.3% vs. 92.5%) and EFS (74.1% vs. 77.5%) rates did not differ significantly (P>0.05). Serial laboratory monitoring revealed that Group T exhibited faster hematological recovery and earlier neutrophil normalization (by week 2 vs. week 4) (P < 0.001). Key inflammatory markers (ferritin, IFN-γ, IL-10) declined rapidly in both groups. Crucially, the ruxolitinib-based strategy drastically reduced chemotherapy exposure: a significantly lower proportion of patients in Group T received glucocorticoids (66.7% vs. 100%, P<0.001) and etoposide (41.7% vs. 100%, P<0.001), and a significantly different distribution of glucocorticoids(Group T median: 60mg/kg (IQR: 0, 60); Group C median: 60mg/kg (IQR:60, 60); P = 0.012)and etoposide(Group T median: 0mg/m2 (IQR: 0, 885.5mg/m2); Group C median: 900mg/m2 (IQR:900, 1000); p=0.000) The incidence of secondary infections and treatment-related laboratory abnormalities (TBil, AST, ALT, or Scr) was comparable between groups. Conclusion: For pediatric HLH, a ruxolitinib-based regimen is a viable and effective therapy. It facilitates more rapid complete remission and markedly reduces chemotherapy exposure, particularly to etoposide, while preserving high short-term survival with an acceptable safety profile. This study provides a compelling rationale for future prospective randomized controlled trials to confirm the long-term benefits and safety of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.